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OBJECTIVE—The (CTG)n polymorphism in the serum carnosi-
nase (CN-1) gene affects CN-1 secretion. Since CN-1 is heavily
glycosylated and glycosylation might inﬂuence protein secre-
tion as well, we tested the role of N-glycosylation for CN-1
secretion and enzyme activity. We also tested whether CN-1
secretion is changed under hyperglycemic conditions.
RESULTS—N-glycosylation of CN-1 was either inhibited by tuni-
camycin in pCSII-CN-1–transfected Cos-7 cells or by stepwise
deletion of its three putative N-glycosylation sites. CN-1 protein
expression, N-glycosylation, and enzyme activity were assessed in
cell extracts and supernatants. The inﬂuence of hyperglycemia on
CN-1 enzyme activity in human serum was tested in homozygous
(CTG)5 diabetic patients and healthy control subjects.
Tunicamycin completely inhibited CN-1 secretion. Deletion of all
N-glycosylation sites was required to reduce CN-1 secretion
efﬁciency. Enzyme activity was already diminished when two
sites were deleted. In pCSII-CN-1–transfected Cos-7 cells cul-
tured in medium containing 25 mmol/l D-glucose, the immature
61 kilodaltons (kDa) CN-1 immune reactive band was not detected.
This was paralleled by an increased GlcNAc expression in cell
lysates and CN-1 expression in the supernatants. Homozygous
(CTG)5 diabetic patients had signiﬁcantly higher serum CN-1 activ-
ity compared with genotype-matched, healthy control subjects.
CONCLUSIONS—We conclude that apart from the (CTG)n
polymorphism in the signal peptide of CN-1, N-glycosylation is
essential for appropriate secretion and enzyme activity. Since
hyperglycemia enhances CN-1 secretion and enzyme activity, our
data suggest that poor blood glucose control in diabetic patients
might result in an increased CN-1 secretion even in the presence
of the (CTG)5 allele. Diabetes 59:1984–1990, 2010
D
iabetic nephropathy (DN) is the foremost cause
for dialysis in the Western world (1). Prime risk
factors for developing DN are poor glycemic
control and high blood pressure; yet, appropri-
ate treatment of individual patients to minimize these risk
factors can only delay the onset, but does not eliminate
susceptibility to develop DN (2,3). We recently demon-
strated that susceptibility to DN is strongly associated
with a polymorphism in the CNDP1 gene (4). This gene
encodes the serum carnosinase (CN-1) protein which
degrades carnosine into -alanine and histidine. We have
also demonstrated that the CNDP1 polymorphism affects
carnosinase secretion, that is, a low CN-1 secretion is
observed when (CTG)5 is present in the signal peptide of
CN-1 (5). This is in line with the ﬁnding that CN-1 activity
is low in (CTG)5 homozygous individuals (4). Overexpres-
sion of CNDP1 in the db/db model results in early onset of
diabetes, whereas in db/db mice that were fed with car-
nosine, the onset of diabetes was delayed and glucose
metabolism was improved (6). This unambiguously shows
the relevance of the carnosine carnosinase system for
diabetic complications, and can also explain why low
serum CN-1 activity is protective. Several mechanisms for
the protective role of carnosine have been postulated
(4,7–10), but deﬁnite proof for its beneﬁcial effect on DN
remains to be assessed.
Although CNDP1 has been conﬁrmed as a susceptibility
locus (11,12), more recently this association was ques-
tioned by Wanic et al. (13). The negative ﬁndings of Wanic
et al. may be explained by the fact that baseline renal
function, proteinuria, and mortality were not included in
their Cox proportional hazards regression analyses (14).
Alternatively, their data might indicate that apart from the
(CTG)n polymorphism, CN-1 secretion is inﬂuenced by
other factors.
N-glycosylation is initiated in the endoplasmatic reticu-
lum (ER) by the transfer of preassembled glucose3-man-
nose9-N-acetylglucosamine2 (Glc)3(Man)9(GlcNAc)2 core
oligosaccharides from the dolichylpyrophosphate carrier
to asparagine residues in nascent proteins. Three different
nucleotide-activated sugar donors are required as sub-
strates for the assembly of dolichol-linked core oligosac-
charides: UDP-N-acetylglucosamine (UDP-GlcNAc), GDP-
mannose, and UDP-glucose. N-glycosidic bonds anchor
the core oligosaccharides to side chains of asparagines
located within a consensus sequence of Asn-X-Thr/Ser.
Not all consensus sequences within a given protein are
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N-glycosylated proteins. Moreover, both the supply of
oligosaccharide substrates and the activity of the oligo-
saccharide-transferring enzyme determines N-glycosyla-
tion efﬁciency. N-glycosylation improves protein stability
and solubility, and act as speciﬁc molecular recognition
sites for the recruitment of chaperones (15). Many pro-
teins need proper N-glycosylation to be correctly folded.
Inaccurately N-glycosylated proteins may therefore not be
secreted, and those that are still secreted may have altered
substrate binding properties and modiﬁed enzyme activity.
The hexosamine biosynthesis pathway is responsible for
both O- and N-glycosylation, using substrates (e.g., fruc-
tose-6P) that are key metabolites in carbon, nitrogen, and
energy homeostasis (16). Hence, the extent of GlcNAc
branching is dependent on enzyme kinetics and metabolic
ﬂux through the hexosamine pathway to generate UDP-
GlcNAc. Lau et al. (17) showed that the-N-glycan branch-
ing pathway cooperates with the number of N-glycans on
glycoproteins to differentially regulate their surface level
in response to hexosamine ﬂux. Similarly, Sasai et al. (18)
demonstrated that the level of UDP-GlcNAc is a critical
factor in the production of 1,6 branched N-glycans. If
high glucose concentrations lead to a higher ﬂux through
the hexosamine (19) pathway, it is conceivable that this
might have potential consequences for N-glycans such as
CN-1. In fact, Bar-On et al. (20) showed in experimental
diabetes that a dolichol-mediated increase in protein N-
glycosylation occurs. They suggest that the dolichol-N-
glycosylation pathway may represent another detrimental
aspect of hyperglycemia and may operate by dolichol mass
action rather than through glycosylating enzyme activity.
CN-1 is a heavily glycosylated protein with three puta-
tive N-glycosylation sites at asparagine N322, N382, and
N402 (21). In the present study, therefore, we investigated
whether N-glycosylation affects CN-1 protein secretion
and enzyme activity of CN-1. Because an increased glu-
cose ﬂux through the hexosamine pathway increases
GlcNAc concentrations (19), we hypothesized that N-
glycosylation of CN-1 is affected by hyperglycemia, result-
ing in an increased CN-1 secretion and enzyme activity.
RESEARCH DESIGN AND METHODS
Construction of CNDP1 mutants. A cDNA clone of the CNDP1 gene
containing six CTG-repeats (RZPD Library 983, entry No BX094414), kindly
provided by Dr. M. Moeller (Department of Nephrology, RWTH, Aachen,
Germany), was used as a template to construct different CNDP1 variants by
PCR. Glycosylation sites of CN-1 were deleted stepwise using the QuikChange
II Site-Directed Mutagenesis Kit (Stratagene Europe, Amsterdam, The Neth-
erlands). In brief, single amino acid exchanges, that is, asparagine for glycine,
were induced in the wild-type CNDP1 cDNA by mutagenic primers. The
sequence of the primers that were used is depicted in Table 1. PCR reactions
were performed according to standard procedures. For mutants lacking one
glycosylation site, either one of the asparagines residues at N322, N382, or
N402 were exchanged. For mutants lacking two glycosylation sites, combina-
tions of residues N322 and N382, N322, and N402 or N382 and N402 were
mutated. Finally, mutants that lack all three N-glycosylation sites at position
N322, N382, and N402 were constructed. All CNDP1 constructs and mutants
were cloned into pCSII  mt vector. For the N-glycosylation-lacking mutants,
stopcodons were removed to generate a myc-tagged CN-1 protein.
Cell culture and transfection. Cos-7 cells (Invitrogen, Karlsruhe, Germany)
were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM, PAA Labora-
tories, Pasching, Austria) enriched with 10% FCS and 1% penicillin/streptomy-
cin at 37°C and 5% CO2. The cells were cotransfected with the various CNDP1
constructs and pCruz-green ﬂuorescent protein (Santa Cruz Biotechnology,
Heidelberg, Germany) by Nanofectin according to the manufacturer’s instruc-
tions (PAA Laboratories). Four hours later, medium was replaced by DMEM
medium containing 1% penicillin/streptomycin. To inhibit N-glycosylation, 10
g/ml of tunicamycin (Sigma-Aldrich Chemie, Steinheim, Germany) was
added to the medium. Cells and supernatants were harvested 48 h later. For
high glucose experiments, Cos-7 cells were transfected with the CNDP1
(CTG)5 variant and cultured for 72 h in DMEM containing 25 mmol/l
D-()-glucose (Sigma-Aldrich) and 1% penicillin/streptomycin. To decrease
GlcNAc production, hexosamine biosynthesis pathway was inhibited by
supplementing 20 mol/l azaserine (Santa Cruz Biotechnology) to the glucose-
conditioned DMEM medium during the incubation period. No cell toxicity was
observed using this concentration, as determined by trypan blue exclusion.
Transfected cells cultured for the same time period in standard medium
(DMEM, 5 mmol/l D-()-glucose, 1% penicillin/streptomycin) were used as
control. Hereafter, supernatants were harvested and transfection efﬁciency
was assessed on an aliquot of the cell suspension by ﬂuorescence-activated
cell sorter analysis using green ﬂuorescent protein as read-out. In general,
transfection efﬁciency was above 70%. In all experiments, supernatants were
concentrated using a Centricon centrifugal ﬁlter device 30,000MW (Millipore,
Schwalbach, Germany). Cells were lysed on ice by addition of 1% Triton X-100
containing lysis buffer, supplemented with 1 mmol/l 1,4-dithiol-DL-threitol
(Fluka Chemie GmbH, Buchs, Germany), phosphatase inhibitor (Sigma-
Aldrich) and protease inhibitor (Roche, Mannheim, Germany). Cell lysates
were centrifuged for 10 min (14,000g at 4°C) to remove insoluble debris.
Western blot analysis. For detection of carnosinase in cell lysates and
supernatants, gel electrophoreses and subsequent Western blotting was
performed. In some experiments, samples were deglycosylated by PNGase F
(New England Biolabs, Frankfurt, Germany) treatment according to the
manufacturer’s recommendations. All samples were boiled for 10 min in
Laemmli sample buffer (Bio-Rad, Mu ¨nchen, Germany) before loading on an 8%
SDS-PAGE. Proteins were transferred electrophoretically to a polyvinylidene
ﬂuoride membrane (Roche, Mannheim, Germany) by semidry blotting. Here-
after the membranes were blocked for1ha troom temperature in TBS-Tween
20 (0.3%, Sigma-Aldrich) containing 10% milk powder. Anti-myc antibody
(Abcam, Cambridge, U.K.) was used for the detection of CN-1 produced by
transfected cells. For detection of CN-1 in human serum samples, mouse
monoclonal anti-CN-1 antibody (Clone RYSK-173, raised against human re-
combinant CN-1) was used. To assess the amount of GlcNAc modiﬁed
proteins, the membranes were incubated overnight with anti-N-acetylglu-
cosamine antibody (Abcam). After incubation with appropriate horseradish-
peroxidase–conjugated secondary antibodies (Santa Cruz Biotechnology)
antibody binding was visualized by enhanced chemiluminescence (PerkinElmer,
Boston, MA). Intensity of the bands was measured by densitometry using ImageJ
1.36b software.
Measurement of carnosinase activity. Serum carnosinase activity (CN1)
was assayed according to a method described by Teufel et al. (21). Shortly, the
reaction was initiated by addition of carnosine and/or homocarnosine and was
stopped by adding 1% trichloracetic acid. Liberated histidine was derivatized
by adding o-phtaldialdehyd, and ﬂuorescence was read using a MicroTek plate
reader (Exc: 360 nm; Em: 460 nm). The recombinant human CN1 was
obtained from R&D Systems (Minneapolis, MN). CN-1 activity in cell super-
natants was normalized to transfection efﬁciency.
Patients. Diabetic patients and healthy control subjects were recruited from
our clinic. Blood samples were collected for measuring CN1 activity as
described above and for CN-1 genotyping as described previously (4). Eleven
(CTG)5 homozygous diabetic patients were identiﬁed (6 female, 5 male; mean
age, 62 years; range 36–84 years). There were 3 type 1 and 8 type 2 diabetic
patients included. Healthy control subjects consisted of 15 individuals (7 male,
TABLE 1
Primers used for site-directed mutagenesis
Forward primer Reverse primer
N322G 5gacctagaagaataccggggtagcagccgggttgagaa3 5ttctcaacccggctgctaccccggtattcttctaggtc3
N382G 5cgtctagtccctcacatgggtgtgtctgcggtggaaaa3 5ttttccaccgcagacacacccatgtgagggactagacg3
N402G 5cttgaagatgtgttctccaaaagaggtagttccaacaagatggttgtttc3 5gaaacaaccatcttgttggaactacctcttttggagaacacatcttcaag3
N-glycosylation sites were step-wise deleted using mutagenic primers. Mismatched base pairs containing the mutations are underlined.
E. RIEDL AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, AUGUST 2010 19858 female; mean age, 41 years; range 36–84 years). Demographic characteris-
tics of patients and control subjects are shown in Table 2. All participants gave
informed consent. Ethical approval was given by the Second Ethics Commit-
tee of Heidelberg University (amendment no. 2 and 3 to ethical approval no.
0193/2001).
Statistical analysis. Quantitative data are given as mean  SD. Student t test
was calculated to compare groups. Values of P  0.05 were considered
statistically signiﬁcant.
RESULTS
N-glycosylation modulates secretion and enzyme ac-
tivity of CN-1. Three CN-1 immunoreactive bands, rang-
ing from 61 to 65 kDa, were found by Western blotting in
cell lysates of pCSII-CNDP1–transfected Cos-7 cells. Al-
though the 65-kDa band was always weakly expressed in
cell lysates, in supernatants it was the most prominent
band. After PNGase F treatment, only the 61-kDa band was
found, suggesting that the lower CN-1 band represents the
immature CN-1 protein devoid of N-glycosylation (Fig. 1).
In human serum, only one CN-1 reactive band was de-
tected corresponding to a molecular weight of 65 kDa.
PNGase F treatment of serum reduced its molecular
weight to 61 kDa (Fig. 1).
To study the role of N-glycosylation for CN-1 protein
secretion, we ﬁrst used tunicamycin to inhibit N-glycosyl-
ation. Tunicamycin is an antibiotic that blocks the reaction
of UDP-GlcNAc and dolicholphosphate; as a consequence,
the synthesis of all N-linked glycoproteins is inhibited.
Tunicamycin completely prevented secretion of CN-1 in
pCSII-CNDP1–transfected cells as demonstrated by West-
ern blotting. CN-1 expression in cell extracts was quanti-
tatively and qualitatively changed by tunicamycin. Only
the immature 61-kDa CN-1 band was detected in signiﬁ-
cantly lower amounts (Fig. 2A).
Because tunicamycin may also affect protein secretion
independent of its inhibitory effect on N-glycosylation, we
constructed myc-tagged CN-1 variants that lack one, two,
or all three putative N-glycosylation sites. To this end,
asparagine residues at N322, N382, and N402 were ex-
changed for glycine. Similar to tunicamycin treatment, the
amount of total CN-1 produced by variants that were
completely devoid of N-glycosylation sites was strongly
decreased compared with wild-type CNDP1 (Fig. 2B). The
low CN-1 expression in these variants was not caused by a
low transfection efﬁciency, since the percentage of green
ﬂuorescent protein-expressing cells was not signiﬁcantly
different compared with wild-type CNDP1-transfected
cells (wild-type, 68%; CNDP1 3, 73%). In the supernatants
of all CNDP1 variants that lack either one, two, or three
N-glycosylation sites, CN-1 expression was lower com-
pared with the wild-type CNDP1 variant (Fig. 2B).
CN-1 secretion efﬁciency, expressed as the proportion
of CN-1 in supernatants to total CN-1 (cell extract 
supernatant) was measured by densitometry. In compari-
son with wild-type CNDP1, CN-1 secretion efﬁciency was
not affected for CN-1 variants lacking one or two N-
glycosylation sites. In contrast, secretion efﬁciency was
severely impaired for variants that lack all three N-glyco-
sylation sites (Fig. 2C). In line with the Western blot, CN-1
enzyme activity in the supernatants decreased when the
number of deleted N-glycosylation sites increased. En-
zyme activity of CN-1 variants lacking only one N-glyco-
sylation site was not signiﬁcantly different to that of
wild-type CN-1. However, enzyme activity of CN-1 variants
lacking two N-glycosylation sites was signiﬁcantly de-
creased (Fig. 2D). The combination of N-glycosylation
sites that were deleted was not important in this regard
(data not shown). As expected, CN-1 activity was not
detected in supernatants of CN-1 variants that were devoid
of N-glycosylation sites.
Hyperglycemia inﬂuences CN-1 secretion and enzyme
activity. Because hyperglycemia results in an increased
glucose ﬂux through the hexosamine pathway and thereby
increases GlcNAc concentrations, we speculated that hy-
perglycemia might increase N-glycosylation and subse-
quently affect CN-1 secretion and activity. Since among the
different genetic CNDP1 (CTG)n variants, CN-1 secretion
is the lowest for the (CTG)5, we chose this variant in the
hyperglycemia experiments. CNDP1 (CTG)5-transfected
cells were cultured for 3 days in high-glucose medium (25
mmol/l D-glucose) (HG) or kept in normal medium con-
taining 5 mmol/l of D-glucose (NG). We ﬁrst tested whether
substrate supply for N-glycosylation, i.e., GlcNAc, was
increased in cells that were cultured in HG medium. As
demonstrated in Fig. 3A, the expression of GlcNAc-modi-
ﬁed proteins was signiﬁcantly increased under hypergly-
cemic conditions. We subsequently tested whether HG
conditions would affect N-glycosylation of CN-1 and to
what extent this inﬂuenced CN-1 secretion and enzyme
activity.
Similarly, as demonstrated in Fig. 1, in cell extracts
obtained from cells that were cultured in NG medium, the
immature non-N-glycosylated 61-kDa band was detected in
Western blot analysis. However, in cells that were cultured
TABLE 2
Demographic characteristics of patients and control subjects
n Age (years) Male/female HbA1c (%)
Duration of DM
(years) RR (n)D R ( n)
Diabetic patients 11 60 (37–76) 5/6 7.4 (6.0–8.4) 17.9 (6–35) 7 3
Control subjects 15 41 (36–84) 7/8 nd 0 No No
All data are expressed as mean. Values in parentheses represent the range; DM, diabetes mellitus; DR, diabetic retinopathy; n, number of
patients; nd, not done; RR, hypertension (deﬁned as repeatedly elevated blood pressure 	140/90 mmHg).
−        − ++ + −
C S C S Hu Hu
65kDa
63kDa
61kDa
PNGase
FIG. 1. CN-1 expression in CNDP1-transfected Cos-7 cells and human
serum. After transfection, cell extracts (C) and supernatants (S) were
harvested as described, and the samples were treated with PNGase ()
or were left untreated (). Similarly, aliquots of human serum (Hu)
were subjected to PNGase treatment. Note that in cell extracts, two
major immunoreactive bands for CN-1 were detected by Western blot
analysis with apparent molecular weight of 61 kDa and 63 kDa,
respectively. The 65-kDa band was prominent in serum and superna-
tants of transfected cells, whereas the expression hereof was weak in
cell extracts. After PNGase treatment, the molecular weight of CN-1 in
serum, supernatants, and cell extracts shifted to 61 kDa. C, cell
extracts; S, supernatants; Hu, human serum.
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gesting a relative increase in N-glycosylation under HG
conditions. This was paralleled by a slight increase in CN-1
expression in the supernatants of these cells (Fig. 3B).
Densitometric quantiﬁcation of immunoblots revealed that
N-glycosylation efﬁciency in cell extracts, expressed as the
proportion of N-glycosylated CN-1 (upper band) to total
CN-1 (upper band  lower band), was signiﬁcantly in-
creased in cells cultured in 25 mmol/l D-glucose containing
medium (Fig. 3C, NG vs. HG, P  0.05). In addition, this
analysis revealed that CN-1 secretion efﬁciency, expressed
as the proportion of CN-1 in cell extract to total CN-1 (cell
extract  supernatant), was signiﬁcantly increased under
hyperglycemic conditions (Fig. 3D, NG vs. HG, P  0.05).
To analyze whether limitation of oligosaccharide substrate
supply would inﬂuence N-glycosylation and secretion efﬁ-
ciency under HG, we used azaserine, an inhibitor of
hexosamine biosynthesis pathway, to impede auxiliary
UDP-GlcNAc formation. Azaserine, as a glutamine analog,
inhibits, among others, the glutamine:fructose-6-phos-
phate amidotransferase enzyme. Restriction of UDP-Glc-
NAc caused a remarkable decrease in CN-1 expression in
the supernatants. Nevertheless, increased N-glycosylation
efﬁciency in cell extracts was not affected by azaserine
conditioning (Fig. 3E).
To test whether our in vitro observations also have an in
vivo relevance, we next addressed whether serum CN-1
activity is different in homozygous (CTG)5 diabetic pa-
tients and genotype-matched healthy control subjects.
Compatible with the in vitro ﬁndings, serum CN-1 activity
was signiﬁcantly higher in diabetic patients (control sub-
jects vs. diabetic patients, P  0.05) (Fig. 4).
DISCUSSION
Secretion of the serum carnosinase is inﬂuenced by the
length of the (CTG)n repeat, located in the signal peptide
of this enzyme (10). Because CN-1 is N-glycosylated, and
glycosylation might inﬂuence protein secretion, stability,
and enzyme activity, it is conceivable that in hyperglyce-
mic patients, CN-1 secretion or activity is not completely
determined by the (CTG)n genotype. In the present study,
we therefore assessed the relevance of N-glycosylation for
CN-1 protein secretion and enzyme activity, and addressed
whether hyperglycemia can inﬂuence serum CN-1 secre-
tion and activity. The main ﬁndings of this study are the
following. First, only deletion of all three N-glycosylation
sites impairs CN-1 secretion efﬁciency, whereas CN-1
activity is already diminished when two sites are deleted.
Second, hyperglycemia increases N-glycosylation efﬁ-
ciency and increases CN-1 secretion. This might be caused
by an increased GlcNAc supply. Third, homozygous
(CTG)5 diabetic patients have higher serum CN-1 activ-
ity compared with genotype-matched healthy control
subjects.
The human CN-1 glycoprotein contains three potential
−             − + +
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FIG. 2. Inﬂuence of N-glycosylation on CN-1 secretion. A: CNDP1-transfected cells were treated with tunicamycin (10 g/ml) () for 48 h or left
untreated (). Hereafter, cell extracts (C) and supernatant (S) were subjected to Western blot analysis. Note that in the presence of
tunicamycin, qualitative and quantitative differences for CN-1 expression in cell extracts were observed, whereas in supernatants of these cells,
no CN-1 expression was found. B: N-glycosylation sites of wild-type CNDP1 were deleted by site-directed mutagenesis. Numbers below the blot
represent the deletion of any one of three (1), any two of three (2), or all three (3) glycosylation sites. The CNDP1 variants were transfected
in Cos-7 cells and expressed as myc-tagged fusion protein as described. Cell extracts (C) and supernatants (S) were subjected to Western blot
analysis using anti-myc antibody. In A and B, the results of a representative blot is depicted. Six different experiments were performed, all with
essentially the same result. C: CN-1 secretion efﬁciency was measured by densitometry of the blots. Secretion efﬁciency was deﬁned as the ratio
of CN-1 in supernatant divided by the total amount of CN-1 (cell extracts  supernatant). The results are expressed as mean ratio  SD of six
individual experiments. D: CN-1 activity in supernatants of wild-type CNDP1-transfected cells and cells expressing CNDP1 variants lacking either
one (1), two (2), or all three (3) glycosylation sites. The results are expressed as mean CN-1 activity (mol/ml/h)  SD. Again, the
supernatants of six individual experiments were included. C, cell extracts; S, supernatants; Hu, human serum; ns, not signifcant; WT, wild-type.
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and N402 (21). In pCSII-CNDP1–transfected Cos-7 cells,
three CN-1 immune reactive bands can be detected. The
61- and 63-kDa bands dominate in cell lysates whereas the
65-kDa band is almost nondetectable in cell extracts. In
contrast, the 65-kDa band is strongly expressed in super-
natants of transfected cells. The different CN-1 bands
detected in Western blotting are likely due to differences in
N-glycosylation, since after PNGase F treatment, only the
61-kDa band was detected. Hence, this band represents
the immature non-N-glycosylated CN-1 protein. Macrohet-
erogeneity occurs for a number of glycosylated proteins
and describes the differential use of glycosylation sites
within a given protein (22–24). The 61- or 63-kDa band was
not found either in serum or in supernatants of transfected
cells. Although this might suggest that CN-1 secretion
occurs only after complete N-glycosylation, our ﬁndings
that CNDP-1 variants lacking one or two glycosylation
sites also secrete CN-1 argues against this assumption. It is
therefore more likely that secretion of the completely
N-glycosylated CN-1 protein is favored, but that complete
N-glycosylation is not a prerequisite for CN-1 secretion.
Nevertheless, when N-glycosylation is completely pre-
vented, either by deletion of all three N-glycosylation sites
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FIG. 3. Inﬂuence of high glucose medium on GlcNAc expression, N-glycosylation of
CN-1, and CN-1 secretion and impact of hexosamine synthesis pathway on CN-1
secretion. CNDP1-transfected Cos-7 cells were cultured for 72 h in the presence
of 25 mmol/l (HG)  20 mol/l azaserine or 5 mmol/l (NG) D-glucose. Hereafter,
cell extracts were prepared and supernatants were harvested. A: Western blot
analysis of GlcNAc modiﬁed proteins in cell extracts. B: Western blot analysis of
CN-1 expression in supernatants (S) and cell extracts (C). Note that the
immature 61-kDa band is not present in cells that were cultured under HG
conditions. In A and B, the results of a representative experiment is depicted.
Four different experiments were performed and all showed similar results. C:
CN-1 glycosylation efﬁciency in cells extracts was measured by densitometry and
deﬁned as ratio of N-glycosylated CN-1 (upper band) to total CN-1 (upper band 
lower band). D: CN-1 secretion efﬁciency was measured as described in Fig. 2.
Four experiments were included. E: Result of a representative Western blot
analysis of CN-1 expression in supernatants (S) and cell extracts (C) of cells
cultured in the presence of HG with () or without () azaserine. Although the secretion of CN-1 is decreased by the limitation of GlcNAc,
azaserine does not inﬂuence the relative increase in N-glycosylation in cell extracts under HG conditions. Four different experiments were
performed, and all showed similar results. C, cell extracts; S, supernatants; HG, 25 mmol/l D-glucose; NG, 5 mmol/l D-glucose.
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impaired. N-glycosylation occurs cotranslationally in the
lumen of the ER and facilitates the protein-folding process
by recruiting members of the calnexin chaperone system
(25). Acquisition of the native structure of the protein may
therefore fail or progress slowly when N-glycosylation is
prevented. Folding-defective or terminally misfolded pro-
teins are disposed from the ER through cytosolic transport
and subsequent proteasomal degradation (26). This might
explain why CN-1 is signiﬁcantly less expressed in cells
transfected with CNDP1 variants that are completely
devoid of N-glycosylation sites as opposed to cells ex-
pressing wild-type CNDP1. The importance of N-glycosyl-
ation of CN-1 for protein secretion is not unique to CN-1 as
it has also been reported for other proteins (24,27,28).
Our data also indicate that CN-1 enzyme activity was
dependent on proper N-glycosylation since deletion of two
N-glycosylation sites signiﬁcantly decreased CN-1 activity.
Enzyme activity as a function of N-glycosylation has also
been reported by other groups (29,30). Why CN-1 activity
severely drops after deletion of two glycosylation sites
remains to be elucidated. Because CN-1 was poorly se-
creted by CNDP1 variants that were devoid of N-glycosyl-
ation sites, no CN-1 activity was detected in supernatants
of these cells as expected.
In diabetic patients, the role of nonenzymatic advanced-
glycation end products for cell activation and damage has
been well studied (31,32). In contrast, the inﬂuence of
enzymatic glycosylation and its possible pathogenic role in
diabetic complications remains to be addressed. A few
studies, however, have reported that hyperglycemia in-
creases N-glycosylation in rats (33–35). Our own data are
in line with this assumption, as we could show that the
immature non-N-glycosylated CN-1 protein was not
present in CNDP1-transfected cells that were grown under
high-glucose conditions. Yet, a possible increase in glyco-
sylation was not reﬂected by a difference in molecular
weight of the mature secreted CN-1 protein. Although
under hyperglycemic conditions, activation of the hex-
osamine pathway leads to synthesis of UDP-GlcNAc (19),
an increase of substrates alone might not be sufﬁcient to
enhance N-glycosylation (36). These conclusions are in
accordance with our observations, since in cells cultured
under HG, N-glycosylation efﬁciency was not disturbed by
inhibition of hexosamine synthesis pathway. Nevertheless,
restriction of UDP-GlcNAc led to decreased CN-1 expres-
sion in the cell supernatants. The assembly of the N-
glycosylation core oligosaccharide is dependent on two
UDP-GlcNAc molecules. Therefore, it is conceivable that
the N-glycosylation and secretion process is slowed down
under azaserine treatment. As expected, azaserine did not
completely block N-glycosylation of CN-1, because the
oligosaccharide substrates can either be synthesized from
glucose or be salvaged from glycoconjugates degraded
within cells. The expression or activity of enzymes that
attach sugars to growing proteins might equally have
contributed to the increased N-glycosylation efﬁciency
under hyperglycemic conditions; these enzymes were not
measured in this study. Hence, it must be emphasized that
the increased CN-1 secretion observed under hyperglyce-
mic conditions may be related to changes in the N-
glycosylation machinery and substrate increment.
If hyperglycemia inﬂuences CN-1 secretion, it is ex-
pected that diabetic patients would have more CN-1
activity compared with genotype-matched healthy control
subjects. Because healthy individuals homozygous for
CNDP1 (CTG)5 have low CN-1 activity (4), we stratiﬁed for
this genotype and compared CN-1 activity of diabetic
patients with that of healthy control subjects. Indeed, our
data show that diabetic patients have signiﬁcantly higher
CN-1 activity. We are aware that this study included only a
relative small group of diabetic patients (n 
 11), and
signiﬁcant differences in the mean age between both
groups were present. Because CN-1 activity increases with
age until adulthood, but not thereafter (37), it is unlikely,
but not excluded, that age differences are a confounding
factor in our analysis. Therefore, these data should be
conﬁrmed in a larger cohort of patients matched for age,
sex, and genotype before ﬁrm conclusions can be drawn.
Recently we showed that CNDP1 activity toward car-
nosine is inhibited by homocarnosine (38). If carnosine is
considered to be protective in terms of diabetic complica-
tions, then clearly other factors than CNDP1 genotype that
also affect carnosine metabolism (e.g., serum homocar-
nosine concentrations and blood glucose control) should
be taken into account for risk assessment for development
of diabetic complications in this group of patients. Dia-
betic patients who do not have the protective CNDP1
genotype might be protected because of good glycemic
control or by having sufﬁcient homocarnosine levels. Vice
versa, diabetic patients with the protective genotype may
still develop DN when glycemic control is poor or when a
low serum concentration of homocarnosine is present.
Inasmuch as our study demonstrates that hyperglycemia
increases CN-1 secretion, it was not our intention to
investigate whether a low CN-1 activity is associated with
a diminished oxidative stress or advanced glycation end
product formation. CN-1 is only one of the parameters that
inﬂuence the amount of serum carnosine. Activity of
carnosine synthase and dietary carnosine intake are two
additional factors. For future studies it would thus also be
worthwhile to study whether CN-1 activity correlates with
carnosine concentrations in diabetic patients and eluci-
date if this in turn correlates with parameters of oxidative
stress and advanced glycosylation end product formation.
We conclude that apart from the (CTG)n polymorphism
in the signal peptide of CN-1, N-glycosylation is essential
for appropriate secretion and enzyme activity. Since hy-
perglycemia enhances CN-1 secretion and enzyme activity,
our data suggest that poor blood glucose control in
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FIG. 4. CN-1 activity was measured in 5L homozygous healthy control
subjects (Co, n  15) as well as in 5L homozygous diabetic patients
(DM, n  11). Results are expressed for each individual patient and
control. The line represents the mean of each group. Co, healthy
control subjects; DM, 5L homozygous diabetic patients.
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tion, even in the presence of the (CTG)5 allele.
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